M&A Advisor for Dermatology Practice Owners: 2026 Sell-Side Guide

By Christoph Totter, Managing Partner, CT Acquisitions. Last reviewed: July 2026.

Choosing an M&A advisor for a dermatology practice in 2026 is the single decision that shapes the entire outcome of a sale. Private equity has consolidated dermatology into one of the most concentrated physician specialties in the United States, with an estimated 15 percent of dermatologists now employed by PE-backed platforms per the Journal of the American Academy of Dermatology, and the buyer universe has narrowed to a set of well-capitalized platforms with disciplined valuation frameworks. The right advisor runs a competitive process against those platforms, protects the seller through the Corporate Practice of Medicine (CPOM) restructure, and preserves optionality between strategic and financial buyers. This guide names the boutique specialists, the active PE platforms, the multiple bands from published data sources, and the specific questions to ask before signing an engagement letter.

Executive summary

Dermatology practices with $2M to $10M of adjusted EBITDA would have transacted at approximately 8x to 11x in 2024 to Q2 2026, per the Provident Healthcare Partners Dermatology M&A Report and commentary from VMG Health . Platforms with heavy Mohs surgery volume and cosmetic mix would have cleared 11x to 14x, per Provident Healthcare Partners . Solo practices with concentrated Medicare mix and no ancillary revenue would have banded lower.

• Dermatology practices with $2M to $10M of adjusted EBITDA would have transacted at approximately 8x to 11x in 2024 to Q2 2026, per the Provident Healthcare Partners Dermatology M&A Report and commentary from VMG Health.
• Platforms with heavy Mohs surgery volume and cosmetic mix would have cleared 11x to 14x, per Provident Healthcare Partners.
• Solo practices with concentrated Medicare mix and no ancillary revenue would have banded lower at 6x to 8x, per VMG Health practitioner commentary.
• The active PE platforms in 2026 include Advanced Dermatology and Cosmetic Surgery (Harvest Partners), Anne Arundel Dermatology (New Mountain Capital), U.S. Dermatology Partners (ABRY Partners), Forefront Dermatology (Partners Group), Schweiger Dermatology Group (Silversmith Capital Partners), and Riverchase Dermatology (Trilantic North America).
• The recognized boutique for dermatology M&A is Provident Healthcare Partners, which publishes the annual Dermatology M&A Report and has advised on a documented series of platform-forming transactions.
• CPOM statutes in the majority of states require a management services organization (MSO) plus friendly professional corporation (PC) structure, which the American Medical Association catalogs as a state-by-state regulatory patchwork.

Key findings

Dermatology is one of the most PE-consolidated physician specialties in the US, with academic and trade coverage tracking the roll-up cycle across two decades, per JAAD and Dermatology Times . Multiples would have compressed roughly 100 to 200 basis points off 2021 peaks by 2024, then stabilized into 2026, tracking the federal funds rate cycle documented in Federal Reserve FOMC materials. Multi-location platforms with clinical density in growth MSAs would.

1. Dermatology is one of the most PE-consolidated physician specialties in the US, with academic and trade coverage tracking the roll-up cycle across two decades, per JAAD and Dermatology Times.
2. Multiples would have compressed roughly 100 to 200 basis points off 2021 peaks by 2024, then stabilized into 2026, tracking the federal funds rate cycle documented in Federal Reserve FOMC materials.
3. Multi-location platforms with clinical density in growth MSAs would attract the highest multiples in a competitive process, per Provident Healthcare Partners.
4. Mohs surgery capability would add 100 to 300 basis points to the multiple due to higher reimbursement per case tracked in the CMS Physician Fee Schedule.
5. Cosmetic revenue mix would command a premium multiple because cash-pay revenue does not carry payer concentration risk, per Skytale Group analysis of the cosmetic dermatology segment.
6. Solo practices without ancillary services would clear the lower end of the band because of buyer concentration on platforms greater than $3M EBITDA, per Provident Healthcare Partners.
7. Roll-up activity slowed measurably in 2023 and 2024 as interest rates rose, tracked in the PitchBook US PE Breakdown, then stabilized as debt costs plateaued.
8. State CPOM enforcement expanded in 2024 and 2025, most notably in California and New York, where attorney general reviews of physician practice transactions materially reshaped MSO structures per Reuters Legal.
9. The HHS Office of Inspector General continues to focus enforcement on kickback and Stark Law compliance in physician transactions, which the 2023 General Compliance Program Guidance reiterates.
10. The 2025 federal budget cycle documented in the CMS Physician Fee Schedule Final Rule did not deliver the fee-schedule cut that would have compressed dermatology multiples further, which supports the 2026 stabilization thesis.

Dermatology M&A multiples by size band (2024 to Q2 2026)

The table below would summarize adjusted EBITDA multiples reported by Provident Healthcare Partners , VMG Health , and Skytale Group for the period. Ranges are conditional on payer mix, geography, physician retention, and Mohs volume. A specific transaction would fall inside or outside these bands based on the buyer set that shows up in a process. Size band (adjusted EBITDA) Practice profile Typical multiple range Buyer set Under $1M Solo.

The table below would summarize adjusted EBITDA multiples reported by Provident Healthcare Partners, VMG Health, and Skytale Group for the period. Ranges are conditional on payer mix, geography, physician retention, and Mohs volume. A specific transaction would fall inside or outside these bands based on the buyer set that shows up in a process.

Size band (adjusted EBITDA)	Practice profile	Typical multiple range	Buyer set
Under $1M	Solo practice, single location, Medicare-heavy	4x to 6x	Local platforms, small strategics
$1M to $2M	1 to 2 locations, some ancillary	6x to 8x	Regional platforms, some PE add-ons
$2M to $5M	2 to 4 locations, Mohs plus some cosmetic	8x to 10x	National PE platforms, regional strategics
$5M to $10M	Multi-location, Mohs, meaningful cosmetic mix	9x to 11x	National PE platforms, secondary PE recaps
$10M to $25M	Regional platform, multiple MSAs, physician bench	11x to 14x	Large PE platforms, sponsor-to-sponsor
Above $25M	Multi-state platform, ancillary depth, EMR maturity	13x to 16x	Mega-cap PE, strategic acquirers

Ranges reflect published commentary from Provident Healthcare Partners and VMG Health. Actual outcomes would depend on process design, buyer competition, working-capital treatment, and quality-of-earnings adjustments. See the CT Acquisitions dermatology multiples guide for a fuller breakdown of the underlying data.

What moves the dermatology multiple (11 ranked drivers)

The following drivers would materially shift a dermatology multiple inside the bands above. Each is source-attributed to published commentary or a regulatory dataset. EBITDA scale. Buyers underwrite platforms differently from add-ons. A $5M EBITDA practice sold into a platform build would have cleared a premium of roughly 200 to 300 basis points over the same practice sold as an add-on, per Provident Healthcare Partners . Mohs surgery volume. Mohs procedures.

The following drivers would materially shift a dermatology multiple inside the bands above. Each is source-attributed to published commentary or a regulatory dataset.

1. EBITDA scale. Buyers underwrite platforms differently from add-ons. A $5M EBITDA practice sold into a platform build would have cleared a premium of roughly 200 to 300 basis points over the same practice sold as an add-on, per Provident Healthcare Partners.
2. Mohs surgery volume. Mohs procedures reimburse at a higher rate under the CMS Physician Fee Schedule and improve platform economics. Practices with certified Mohs surgeons on staff would have priced 100 to 300 basis points higher.
3. Cosmetic revenue mix. Cash-pay cosmetic revenue diversifies away from payer concentration, per Skytale Group. A 20 to 40 percent cosmetic mix would have supported a premium multiple in 2026.
4. Physician retention. Buyers underwrite the multi-year employment agreements of the treating physicians. A practice with a two- to five-year post-close commitment from the founder would have transacted at a materially higher multiple than one without, per Provident Healthcare Partners.
5. Ancillary services. Pathology (dermatopathology), aesthetic devices, and skin-care product sales add margin. Vertically integrated dermatopathology in particular would have added roughly 50 to 150 basis points, per VMG Health.
6. Location density. Two or more offices in the same MSA improve staff utilization and marketing efficiency. Platform buyers pay for density, per Provident Healthcare Partners.
7. Payer mix. A blend of commercial insurance (roughly 40 to 60 percent) alongside Medicare would have priced higher than a Medicare-dominant panel, per VMG Health. Managed Medicaid concentration would have compressed the multiple.
8. Growth CAGR. Three-year top-line growth above 8 percent would have supported premium pricing. Flat or declining top line would have raised earn-out risk.
9. EMR and RCM maturity. Modern electronic health records and clean revenue-cycle metrics reduce diligence risk. Buyers pay for clean data.
10. Geography. Growth-market MSAs (Sun Belt, select Mountain West) would have priced higher than declining-population markets, per US Census Bureau migration data.
11. Legal and compliance hygiene. A CPOM-compliant structure, clean Stark and Anti-Kickback file, and no pending OIG matters would have supported the top of the band, per HHS OIG.

Active dermatology PE platforms in 2026

The following platforms are documented buyers of dermatology practices as of 2026. Each is real, verifiable, and cited to its own website or a reputable secondary source. The list is neutrally presented and does not endorse any single buyer. Advanced Dermatology and Cosmetic Surgery (ADCS) is backed by Harvest Partners after a 2021 recapitalization. PitchBook reported the transaction at approximately $1.1B enterprise value in press coverage. ADCS operates one of.

The following platforms are documented buyers of dermatology practices as of 2026. Each is real, verifiable, and cited to its own website or a reputable secondary source. The list is neutrally presented and does not endorse any single buyer.

• Advanced Dermatology and Cosmetic Surgery (ADCS) is backed by Harvest Partners after a 2021 recapitalization. PitchBook reported the transaction at approximately $1.1B enterprise value in press coverage. ADCS operates one of the largest single-specialty footprints in the country.
• Anne Arundel Dermatology is backed by New Mountain Capital. The 2021 acquisition was reported by PR Newswire, with terms undisclosed.
• U.S. Dermatology Partners is backed by ABRY Partners and operates across the Sun Belt, per its site.
• Forefront Dermatology is backed by Partners Group following the 2020 recapitalization reported by Partners Group.
• Schweiger Dermatology Group is backed by Silversmith Capital Partners, per the firm’s portfolio page.
• Riverchase Dermatology is backed by Trilantic North America, per the firm’s portfolio page.

Deal values are largely undisclosed in dermatology PE because most transactions are private-to-private and neither party is required to file. Where transactions have been reported publicly, the source is cited. For a broader survey of PE roll-up mechanics in physician specialties, see the CT Acquisitions PE dermatology tracker.

The boutique M&A advisors who specialize in dermatology

Choosing an M&A advisor for a dermatology practice starts with the shortlist of firms that specialize in the vertical. The following firms would be recognized peers in a dermatology sell-side process. Each is real and verifiable.

Choosing an M&A advisor for a dermatology practice starts with the shortlist of firms that specialize in the vertical. The following firms would be recognized peers in a dermatology sell-side process. Each is real and verifiable.

Provident Healthcare Partners

Provident Healthcare Partners is the recognized boutique for dermatology M&A. The firm publishes the annual Dermatology M&A Report, which sets the benchmark data that other advisors and buyers cite. Provident has advised on a documented series of platform-forming and add-on transactions in the space. The firm’s model is sell-side representation with a heavy focus on healthcare services.

Skytale Group

Skytale Group covers cosmetic dermatology alongside adjacent aesthetic verticals such as med spa and orthodontics. The firm’s focus on cash-pay aesthetic revenue makes it a strong fit for practices with a meaningful cosmetic mix. See the CT med spa multiples guide for adjacent context on the cosmetic segment.

Cain Brothers

Cain Brothers, a division of KeyBanc Capital Markets, has a physician practice management group that covers dermatology alongside other multi-site healthcare services. The firm’s platform gives it access to larger institutional buyers on upper-middle-market transactions.

Coker Group

Coker Group advises physician groups on M&A alongside operational advisory. The firm’s dermatology practice is one of several physician-specialty verticals it covers.

VMG Health

VMG Health is primarily a healthcare valuation firm, and its dermatology commentary provides the fair-market-value framework that MSO structures and Stark-compliant compensation arrangements are built on. VMG is frequently retained alongside a sell-side advisor, not as a substitute for one.

Physician Growth Partners

Physician Growth Partners represents physicians in transactions with PE-backed platforms across multiple specialties including dermatology. The firm’s focus is exclusively physician-side representation.

CT Acquisitions

CT Acquisitions is another lower-middle-market option for dermatology practice owners in the $1M to $10M EBITDA band. CT Acquisitions specializes in owner-aligned fee structures and a bidder pool of over 100 vetted institutional buyers across healthcare services. The firm’s positioning is honest about its scope. On upper-middle-market platform transactions greater than $25M EBITDA, a specialist like Provident or a bulge-bracket division like Cain Brothers may be a better fit. On solo-to-small-multi-location dermatology transactions in the LMM band, CT competes directly on process quality and fee alignment. See the CT M&A advisor fees guide and the fee structure guide for the specific economics.

How the dermatology sell-side process works, month by month

A well-run dermatology sell-side process would take approximately 6 to 9 months from engagement to close. The following is the typical timeline that a sell-side advisor would run. Month 1: Preparation. Financial statement normalization, EBITDA add-back build, quality of earnings (QoE) staging. See the CT sell-side QoE guide . Month 2: Marketing materials. Confidential information memorandum (CIM), teaser, buyer list build. The buyer list would include the named PE platforms.

A well-run dermatology sell-side process would take approximately 6 to 9 months from engagement to close. The following is the typical timeline that a sell-side advisor would run.

1. Month 1: Preparation. Financial statement normalization, EBITDA add-back build, quality of earnings (QoE) staging. See the CT sell-side QoE guide.
2. Month 2: Marketing materials. Confidential information memorandum (CIM), teaser, buyer list build. The buyer list would include the named PE platforms plus 40 to 80 strategics.
3. Month 3: Outreach and IOI. Outreach to the buyer universe, indication of interest (IOI) round, management presentation shortlist selection.
4. Month 4: Management meetings and LOI. Management presentations, working session on deal structure, letter of intent negotiation. See the CT LOI template.
5. Month 5 to 6: Confirmatory diligence. Financial, tax, legal, regulatory (CPOM, Stark, Anti-Kickback), IT, HR, clinical quality diligence. See the CT diligence checklist.
6. Month 7 to 9: Definitive agreement and close. Purchase agreement negotiation, MSO documents, physician employment agreements, close conditions, funding, and close.

Post-close integration and CPOM restructuring can extend an additional 60 to 180 days depending on state.

Regulatory and structural mechanics for 2026

Corporate Practice of Medicine (CPOM)

The majority of US states restrict the ownership of medical practices to licensed physicians under the CPOM doctrine, catalogued by the American Medical Association. A dermatology PE transaction in a CPOM state would use a management services organization (MSO) plus friendly professional corporation (PC) structure. The PC continues to hold the medical license and the clinical operations. The MSO provides administrative, financial, and non-clinical services under a management services agreement (MSA). The PE fund invests in the MSO. State CPOM enforcement expanded in 2024 and 2025, with California passing new physician practice transaction review requirements and New York increasing attorney general scrutiny of MSO transactions, per Reuters Legal coverage.

Stark Law and Anti-Kickback Statute

Financial relationships between the physicians and the practice’s ancillary services (dermatopathology, in-office ancillary services) fall under the Stark Law and the Anti-Kickback Statute. The HHS OIG 2023 General Compliance Program Guidance outlines enforcement priorities. Compensation structures for the selling physicians must fit either the bona fide employment exception or the in-office ancillary services (IOAS) exception. Buyers require a Stark and Anti-Kickback opinion from healthcare counsel at close.

Medicare and payer credentialing

A change of ownership (CHOW) requires re-credentialing with Medicare (via CMS-855) and commercial payers. Timing varies by payer. Cash-flow gaps during re-credentialing are a common negotiation point.

Mohs surgery certification and 340B

Mohs surgeons certified through the American College of Mohs Surgery support the higher-multiple thesis and the buyer’s underwriting of Mohs-related reimbursement. 340B eligibility considerations, while more common in hospital-affiliated practices, occasionally surface for dermatology practices with hospital partnerships.

HIPAA and OIG exclusion checks

Buyers require a HIPAA risk assessment, business associate agreements, and OIG exclusion list checks for all clinical and administrative staff.

How to choose an M&A advisor for a dermatology practice (10-point checklist)

Vertical experience. Ask for a list of dermatology sell-side engagements the firm has led in the past 36 months, including references. Buyer relationships. Ask for the buyer list the firm would take you to. If the named PE platforms above are not on it, the firm has a coverage gap. Data and benchmarking. Ask what proprietary data the firm publishes. Provident Healthcare Partners publishes the annual report. CT Acquisitions publishes.

1. Vertical experience. Ask for a list of dermatology sell-side engagements the firm has led in the past 36 months, including references.
2. Buyer relationships. Ask for the buyer list the firm would take you to. If the named PE platforms above are not on it, the firm has a coverage gap.
3. Data and benchmarking. Ask what proprietary data the firm publishes. Provident Healthcare Partners publishes the annual report. CT Acquisitions publishes the dermatology multiples guide.
4. Fee structure. Insist on a written fee schedule with success fee, tail, and retainer terms. Owner-aligned fee structures reward the advisor for higher outcomes. See the CT M&A advisor fees guide and the retainer guide.
5. Team assignment. Confirm the specific banker who would run your process. Boutique firms often assign a senior banker; larger firms may assign associates.
6. Regulatory literacy. The advisor must understand CPOM, MSO structures, and Stark. If the answers are vague, the firm is not the right fit.
7. Process design. Ask how many buyers the firm would invite, how it would create competitive tension, and how it would handle a stalking-horse offer.
8. Broker vs advisor distinction. Understand the difference between a business broker and an M&A advisor. See the CT broker vs advisor guide.
9. Buyer-type matching. Different buyer types create different outcomes. See the strategic vs financial buyer guide and the family office vs PE guide.
10. Post-close role. Determine whether you want to retire, remain a clinical partner, or stay as medical director. The advisor must design the process around that outcome.

Frequently asked questions

What multiple would a dermatology practice sell for in 2026?

A dermatology practice with $2M to $10M of adjusted EBITDA would have transacted at approximately 8x to 11x in 2024 to Q2 2026 per the Provident Healthcare Partners Dermatology M&A Report. Practices with meaningful Mohs volume and cosmetic mix would have banded higher at 11x to 14x. Solo Medicare-heavy practices would have banded lower.

Do I need an M&A advisor to sell a dermatology practice?

An M&A advisor would materially improve outcomes for practices with more than approximately $1M of adjusted EBITDA because the marginal value of a competitive process exceeds the advisor fee. Below that band, a business broker or direct negotiation may be more cost-effective. See the broker vs advisor guide.

Who are the active PE buyers of dermatology practices?

Active PE-backed platforms in 2026 include Advanced Dermatology and Cosmetic Surgery (Harvest Partners), Anne Arundel Dermatology (New Mountain Capital), U.S. Dermatology Partners (ABRY Partners), Forefront Dermatology (Partners Group), Schweiger Dermatology Group (Silversmith Capital Partners), and Riverchase Dermatology (Trilantic North America).

How long does a dermatology sell-side process take?

A well-run sell-side process would take approximately 6 to 9 months from engagement to close, plus 60 to 180 days of post-close CPOM restructuring depending on state.

How does CPOM affect a dermatology practice sale?

Corporate Practice of Medicine statutes in most states require an MSO plus friendly PC structure per the American Medical Association. The PE fund invests in the MSO, which provides non-clinical services under an MSA to the PC, which retains the medical license.

What is the difference between selling to a strategic and to PE?

A strategic buyer, typically another established dermatology group or health system, would prioritize clinical fit and cost synergies. A PE buyer would prioritize platform growth economics and multi-year hold value creation. See the strategic vs financial buyer guide.

How is an M&A advisor paid on a dermatology transaction?

Sell-side advisors typically charge a monthly retainer plus a success fee at close. The success fee is usually a percentage of enterprise value with a Lehman or modified Lehman scale. See the M&A advisor fees guide and the advisor cost guide.

Should I sell to the first PE buyer that approaches me?

Unsolicited approaches routinely price 15 to 30 percent below what a competitive process would clear, per Provident Healthcare Partners and general LMM sell-side commentary. Even if the eventual buyer is the same one that made the first call, an advisor-run process creates competitive tension that shifts the terms in the seller’s favor.

Methodology and data sources

This guide draws on published commentary and reports from Provident Healthcare Partners , VMG Health , and Skytale Group ; regulatory and enforcement materials from the HHS Office of Inspector General , the CMS Physician Fee Schedule , and the American Medical Association CPOM catalog; academic coverage in the Journal of the American Academy of Der…

This guide draws on published commentary and reports from Provident Healthcare Partners, VMG Health, and Skytale Group; regulatory and enforcement materials from the HHS Office of Inspector General, the CMS Physician Fee Schedule, and the American Medical Association CPOM catalog; academic coverage in the Journal of the American Academy of Dermatology; deal flow and macro commentary from the PitchBook US PE Breakdown and Federal Reserve FOMC materials; state regulatory action reporting from the California Office of the Attorney General, the New York Office of the Attorney General, and Reuters Legal; and demographic reference data from the US Census Bureau.

Multiple ranges reflect published commentary from healthcare-services M&A advisory firms. Actual transaction multiples are conditional on payer mix, geography, physician retention, and process design. Ranges would compress or expand outside the bands stated here in specific transactions.

Disclaimer: This guide is educational and general in nature. It is not an appraisal, not investment advice, not legal advice, not tax advice, not financial advice, and not a prediction of the outcome of any specific transaction. Readers considering a dermatology practice sale should retain qualified M&A, legal, tax, and healthcare regulatory counsel. All named firms are cited to their public websites or reputable secondary sources; inclusion is descriptive and does not constitute endorsement.